---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066932"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:50:58.980904+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tectonic Q1 net loss $15.9M; cash $306M; TX45 Phase 1b shows PCWP reduction 17.9%

## Summary
- Net loss of $15.9M for Q1 2025 vs $15.2M in Q1 2024; R&D expenses $13.0M, G&A $5.3M.
- Cash and equivalents $306.2M as of Mar 31, 2025, providing runway into Q4 2028; $185M PIPE closed Feb 2025.
- TX45 Phase 1b Part A: 17.9% reduction in PCWP in PH-HFpEF; >30% PVR reduction in CpcPH subgroup.
- Full Phase 1b Part A data to be presented May 17, 2025 at ESC Heart Failure Congress.
- Part B of TX45 Phase 1b (PH-HFrEF) enrolling; topline expected 2H 2025; APEX Phase 2 data expected 2026.

## SEC filing metadata
- accession: 0000950170-25-066932
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/0000950170-25-066932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000095017025066932/tecx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066932
- JSON: https://secwatch.observer/filing/0000950170-25-066932.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.